# Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

> **NCT05168930** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 45 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT05168930
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-18
- **Primary completion:** 2026-10-28
- **Final completion:** 2028-10-28
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05168930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05168930, "Zanubrutinib and Venetoclax in CLL (ZANU-VEN)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05168930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*